8-K: Xencor Reports First Quarter 2024 Financial Results, Advances Clinical Pipeline

Xencor announced its first quarter 2024 financial results, highlighting progress in its clinical programs and the approval of Ultomiris for NMOSD.

Summary

• Xencor reported a net loss of $68.0 million, or $(1.11) per share, for the first quarter of 2024, compared to a net loss of $60.8 million, or $(1.02) per share, for the same period in 2023.
• The company's revenue for the quarter was $12.8 million, down from $19.0 million in the first quarter of 2023, due to a shift from milestone revenue to non-cash royalty revenue.
• Research and development expenses decreased to $56.9 million from $65.6 million in the prior year, reflecting changes in spending across multiple clinical-stage programs and wind-down costs on terminated programs.
• Xencor's cash, cash equivalents, and marketable debt securities totaled $646.7 million as of March 31, 2024, compared to $697.4 million at the end of 2023.
• The company expects to end 2024 with between $475 million and $525 million in cash and believes it has sufficient funds to support operations into 2027.
• Xencor is advancing its clinical pipeline with a focus on bispecific CD3 and CD28 T cell engagers, including XmAb819, XmAb808, and XmAb541, all in Phase 1 clinical studies.
• The first patient was dosed in a Phase 1 study of XmAb541, a bispecific antibody for CLDN6-positive tumors.
• Ultomiris, which incorporates Xencor's Xtend Fc Domain, was approved in the U.S. for adult patients with NMOSD, and a single dose of an investigational antibody with Xtend showed up to 77% effectiveness in preventing malaria in children for six months.

Sentiment

Score: 5

Explanation: The document presents mixed results with a decrease in revenue and an increase in net loss, but also highlights positive clinical advancements and a strong cash position. The sentiment is neutral to slightly negative due to the financial results.

Positives

• Xencor's Xtend technology continues to show clinical validation with the approval of Ultomiris for NMOSD and the positive malaria prevention results.
• The company has a strong cash position of $646.7 million as of March 31, 2024, and expects to have sufficient funds to support operations into 2027.
• Xencor is advancing its clinical pipeline with multiple programs in Phase 1 clinical studies, including XmAb819, XmAb808, and XmAb541.
• The first patient was dosed in a Phase 1 study of XmAb541, a bispecific antibody for CLDN6-positive tumors.
• The company has appointed a new Chief Financial Officer, Bart Cornelissen.

Negatives

• Xencor's revenue decreased to $12.8 million in the first quarter of 2024, compared to $19.0 million in the same period of 2023.
• The company's net loss increased to $68.0 million, or $(1.11) per share, in the first quarter of 2024, compared to $60.8 million, or $(1.02) per share, in the same period of 2023.
• Other expenses increased significantly to $10.8 million due to an impairment charge on equity investments.

Risks

• The company's financial results are subject to the risks associated with drug development, including clinical trial outcomes and regulatory approvals.
• The company's future financial performance is dependent on the success of its clinical programs and the commercialization of its products.
• The company's cash position is expected to decrease by the end of 2024, although it is expected to be sufficient to fund operations into 2027.
• The company's increased other expenses due to impairment charges on equity investments could impact future profitability.

Future Outlook

Xencor expects to end 2024 with between $475 million and $525 million in cash, cash equivalents and marketable debt securities, and to have cash to fund research and development programs and operations into 2027.

Management Comments

• Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor, stated that they have focused their XmAb clinical pipeline and discovery activities on bispecific CD3 and CD28 T cell engagers.
• Bassil Dahiyat also mentioned that they plan to select their next T cell engager IND candidate later this year.

Industry Context

Xencor's focus on bispecific antibodies and T cell engagers aligns with the broader industry trend towards developing more targeted and effective cancer therapies. The approval of Ultomiris, which incorporates Xencor's Xtend technology, highlights the growing importance of antibody engineering in improving treatment outcomes.

Comparison to Industry Standards

• Xencor's revenue decline is not uncommon for clinical-stage biopharmaceutical companies that are transitioning from milestone-based revenue to royalty-based revenue.
• The decrease in R&D spending is typical as companies adjust their focus and wind down certain programs.
• The cash position of $646.7 million is relatively strong for a company of this size and stage, providing a runway for continued development.
• The approval of Ultomiris is a significant milestone, demonstrating the value of Xencor's technology and its potential to generate future revenue streams, similar to other companies with successful antibody engineering platforms such as Regeneron and Genmab.
• The malaria prevention results are also notable, showcasing the potential of Xencor's technology in areas beyond oncology, similar to companies like Moderna and BioNTech that have expanded their focus beyond their initial therapeutic areas.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased revenue, but encouraged by the clinical advancements and strong cash position.
• Employees may be positively impacted by the company's continued progress and financial stability.
• Patients may benefit from the development of new therapies using Xencor's technology.
• Partners may be encouraged by the clinical validation of Xencor's technology and the approval of Ultomiris.

Next Steps

• Xencor plans to select its next T cell engager IND candidate later this year.
• Company management will participate in the RBC Capital Markets Global Healthcare Conference on May 14, 2024, and the BofA Securities Health Care Conference on May 15, 2024.

Key Dates

Keywords

Xencor, XmAb, bispecific antibodies, T cell engagers, cancer, clinical trials, Ultomiris, NMOSD, malaria, biopharmaceutical, financial results, antibody engineering